Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic interferon therapy of multiple sclerosis: the pros.

R L Knobler1

  • 1Department of Neurology, Jefferson Medical College, Philadelphia, PA 19107.

Neurology
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utililization of experimental animal model for correlative multispectral MRI and pathological analysis of brain tumors.

Magnetic resonance imaging·1999
Same author

Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.

Neurology·1999
Same author

Modulation of T cell-endothelial adhesion by astrocyte conditioned medium.

Glia·1998
Same author

Improved intracranial lesion characterization by tissue segmentation based on a 3D feature map.

Magnetic resonance in medicine·1997
Same author

A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis.

Neurology·1997
Same author

Formation of undifferentiated mesenteric tumors in transgenic mice expressing human neurotropic polymavirus early protein.

Oncogene·1996

Interferon (IFN) showed promise for multiple sclerosis (MS) by reducing exacerbations in a placebo-controlled trial. However, side effects and immune complex formation limited its use, particularly with older preparations.

Area of Science:

  • Neuroimmunology
  • Viral Immunology

Background:

  • Multiple sclerosis (MS) pathogenesis involves immune responses in genetically susceptible individuals, potentially triggered by viral infections.
  • Interferon (IFN) possesses antiviral and immunomodulatory properties, suggesting therapeutic potential for MS.

Purpose of the Study:

  • To evaluate the efficacy and safety of systemic natural alpha interferon in patients with exacerbating-remitting multiple sclerosis.
  • To investigate the role of immune complex formation in interferon-related side effects.

Main Methods:

  • A randomized, double-blind, placebo-controlled, crossover trial involving 24 patients with MS.
  • Systemic natural alpha interferon was administered, and outcomes were compared to placebo.

Main Results:

Related Experiment Videos

  • Patients with a strictly exacerbating-remitting course experienced reduced frequency and severity of exacerbations.
  • Patients with chronic progressive MS did not benefit and experienced side effects like fever, malaise, and fatigue.
  • Immune complexes, caused by antibodies to residual Sendai virus proteins, were identified as a source of side effects.

Conclusions:

  • Alpha interferon may benefit certain MS patient groups, but side effects and preparation purity are critical concerns.
  • Further clinical trials, especially focusing on more purified beta interferon preparations, are warranted for MS treatment.